The Asclepius Innovation Prize
Awarded to the medical organization that introduced a clinically validated treatment or diagnostic method that materially changed the standard of care for a widespread condition.

OUR IMPACT
A Commitment to Clarity
Meridial's oncology research division developed the ClearMark liquid biopsy panel in partnership with three academic medical centers. The panel detects a novel set of circulating tumor markers with 94% sensitivity at stage I, a threshold previously considered unachievable without invasive tissue sampling. The Asclepius committee described the contribution as "a rare instance of a single institution bending the survival curve for one of medicine's most resistant diseases."


